Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAXXAIR Trial
2023-506166-31-01Phase 4Completed
- Sponsor
- Gentofte Hospital
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in influenza comparing Intranasal live attenuated influenza vaccine, Intramuscular inactivated influenza vaccine and Placebo control (3 arms). Primary endpoints: Antigen-activated CD4+ T-lymphocytes and Mucosal antibody response to vaccine haemagglutinin antigens. Started Jan 2024; status: completed.
02
Drugs
live attenuated influenza vaccineinfluenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2023-506166-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506166-31-01.